🚀 VC round data is live in beta, check it out!
Humacyte Valuation Multiples
Discover revenue and EBITDA valuation multiples for Humacyte and similar public comparables like Oramed Pharmaceuticals, Medinice, Tiziana Life Sciences, Abionyx Pharma and more.
Humacyte Overview
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Founded
2020
HQ
Employees
220
Website
Financials (LTM)
EV
$172M
Humacyte Financials
Humacyte reported last 12-month revenue of $5M.
In the same LTM period, Humacyte generated ($3M) in gross profit and had net loss of ($54M).
Revenue (LTM)
Humacyte P&L
In the most recent fiscal year, Humacyte reported revenue of $2M and EBITDA of ($22M).
Humacyte expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | ($3M) | XXX | ($8M) | XXX | XXX | XXX |
| Gross Margin | (61%) | XXX | (376%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($22M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1091%) | XXX | XXX | XXX |
| EBIT Margin | (2107%) | XXX | (5305%) | XXX | XXX | XXX |
| Net Profit | ($54M) | XXX | ($41M) | XXX | XXX | XXX |
| Net Margin | (1130%) | XXX | (2004%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Humacyte Stock Performance
Humacyte has current market cap of $157M, and enterprise value of $172M.
Market Cap Evolution
Humacyte's stock price is $0.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $172M | $157M | 0.0% | XXX | XXX | XXX | $-0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHumacyte Valuation Multiples
Humacyte trades at 36.0x EV/Revenue multiple, and (7.7x) EV/EBITDA.
EV / Revenue (LTM)
Humacyte Financial Valuation Multiples
As of April 20, 2026, Humacyte has market cap of $157M and EV of $172M.
Equity research analysts estimate Humacyte's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Humacyte has a P/E ratio of (2.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV (current) | $172M | XXX | $172M | XXX | XXX | XXX |
| EV/Revenue | 36.0x | XXX | 84.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.7x) | XXX | XXX | XXX |
| EV/EBIT | (1.7x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/Gross Profit | (59.0x) | XXX | (22.4x) | XXX | XXX | XXX |
| P/E | (2.9x) | XXX | (3.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Humacyte Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Humacyte Margins & Growth Rates
Humacyte's revenue in the last 12 month grew by 450%.
Humacyte's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Humacyte Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 450% | XXX | 449% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1091%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (83%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 659% | XXX | 1530% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1393% | XXX | 3405% | XXX | XXX | XXX |
| Opex to Revenue | 2117% | XXX | 5168% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Humacyte Public Comps
See public comps and valuation multiples for other Medical Devices and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Humacyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Oramed Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Medinice | XXX | XXX | XXX | XXX | XXX | XXX |
| Tiziana Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Abionyx Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Molecular Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Humacyte M&A Activity
Humacyte acquired XXX companies to date.
Last acquisition by Humacyte was on XXXXXXXX, XXXXX. Humacyte acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Humacyte
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHumacyte Investment Activity
Humacyte invested in XXX companies to date.
Humacyte made its latest investment on XXXXXXXX, XXXXX. Humacyte invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Humacyte
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Humacyte
| When was Humacyte founded? | Humacyte was founded in 2020. |
| Where is Humacyte headquartered? | Humacyte is headquartered in United States. |
| How many employees does Humacyte have? | As of today, Humacyte has over 220 employees. |
| Who is the CEO of Humacyte? | Humacyte's CEO is Laura E. Niklason. |
| Is Humacyte publicly listed? | Yes, Humacyte is a public company listed on Nasdaq. |
| What is the stock symbol of Humacyte? | Humacyte trades under HUMA ticker. |
| When did Humacyte go public? | Humacyte went public in 2021. |
| Who are competitors of Humacyte? | Humacyte main competitors are Oramed Pharmaceuticals, Medinice, Tiziana Life Sciences, Abionyx Pharma. |
| What is the current market cap of Humacyte? | Humacyte's current market cap is $157M. |
| What is the current revenue of Humacyte? | Humacyte's last 12 months revenue is $5M. |
| What is the current revenue growth of Humacyte? | Humacyte revenue growth (NTM/LTM) is 450%. |
| What is the current EV/Revenue multiple of Humacyte? | Current revenue multiple of Humacyte is 36.0x. |
| Is Humacyte profitable? | No, Humacyte is not profitable. |
| What is the current net income of Humacyte? | Humacyte's last 12 months net income is ($54M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.